Top

Published in:

01-07-2014 | Research Article

CYP17 polymorphism (rs743572) is associated with increased risk of gallbladder cancer in tobacco users

Authors: Rajani Rai, Kiran L. Sharma, Sanjeev Misra, Ashok Kumar, Balraj Mittal

Published in: Tumor Biology | Issue 7/2014

Abstract

Gallbladder cancer (GBC) involves interplay of sex steroids, including estrogen and progesterone. Since CYP17 is a key enzyme involved in estrogen and testosterone hormone biosynthesis as well as in xenobiotic metabolism, it may be a potential candidate gene in the carcinogenesis of the gallbladder. Hence, the present study aimed to investigate the association of CYP17 (rs2486758, and rs743572) polymorphisms with GBC susceptibility. The present study included a total of 414 histologically confirmed GBC and 230 healthy controls. The CYP17 (rs2486758 and rs743572) polymorphisms were genotyped by TaqMan-Allele discrimination assays. Statistical analysis was performed by using SPSS ver. 16. Overall, both the CYP17 SNPs did not indicate any association with GBC risk at genotype, haplotype, or at the genotypic interaction levels. However, in the case-only analysis, CYP rs743572 showed association with increased risk of GBC in tobacco users at hetero genotype and dominant models, as compared to non-user GBC patients. The TC_rs2486758-AG_rs743572 genotypic combination was also associated with increased GBC susceptibility in tobacco users. CYP17 rs743572 is associated with increased risk of GBC in tobacco users in the North Indian population. However, the study requires confirmation in other populations.

Wang F, Wang B, Qiao L. Association between obesity and gallbladder cancer. Front Biosci (Landmark Ed). 2012;17:2550–8.CrossRef

Misra S, Chaturvedi A, Misra NC. Gallbladder cancer. Curr Treat Options Gastroenterol. 2006;9:95–106.CrossRefPubMed

Sheth S, Bedford A, Chopra S. Primary gallbladder cancer: recognition of risk factors and the role of prophylactic cholecystectomy. Am J Gastroenterol. 2000;95:1402–10.CrossRefPubMed

Baez S, Tsuchiya Y, Calvo A, Pruyas M, Nakamura K, Kiyohara C, et al. Genetic variants involved in gallstone formation and capsaicin metabolism, and the risk of gallbladder cancer in Chilean women. World J Gastroenterol. 2010;16:372–8.PubMedCentralCrossRefPubMed

Tsuchiya Y, Terao M, Okano K, Nakamura K, Oyama M, Ikegami K, et al. Mutagenicity and mutagens of the red chili pepper as gallbladder cancer risk factor in Chilean women. Asian Pac J Cancer Prev. 2011;12:471–6.PubMed

Dwivedi S, Madeshiya A, Singh D, Singh S, Krishna A. Gall bladder cancer and some epidemiological factors: a cross sectional study. Biomed Res. 2013;24:83–7.

Gabbi C, Kim HJ, Barros R, Korach-Andre M, Warner M, Gustafsson JA. Estrogen-dependent gallbladder carcinogenesis in lxrbeta−/− female mice. Proc Natl Acad Sci U S A. 2010;107:14763–8.PubMedCentralCrossRefPubMed

Srivastava A, Sharma KL, Srivastava N, Misra S, Mittal B. Significant role of estrogen and progesterone receptor sequence variants in gallbladder cancer predisposition: a multi-analytical strategy. PLoS One. 2012;7:e40162.PubMedCentralCrossRefPubMed

Xu J, Lin X, Zhu H, Zhang Z, Yang B. Genetic variation of the cyp17 and susceptibility to endometrial cancer: a meta-analysis. Mol Biol Rep. 2013;40:5085–91.CrossRefPubMed

10.

Sakoda LC, Blackston C, Doherty JA, Ray RM, Lin MG, Stalsberg H, et al. Polymorphisms in steroid hormone biosynthesis genes and risk of breast cancer and fibrocystic breast conditions in Chinese women. Cancer Epidemiol Biomarkers Prev. 2008;17:1066–73.PubMedCentralCrossRefPubMed

11.

Stanford JL, Noonan EA, Iwasaki L, Kolb S, Chadwick RB, Feng Z, et al. A polymorphism in the cyp17 gene and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2002;11:243–7.PubMed

12.

Tuzuner BM, Ozturk T, Kisakesen HI, Ilvan S, Zerrin C, Ozturk O, et al. Cyp17 (t-34c) and cyp19 (trp39arg) polymorphisms and their cooperative effects on breast cancer susceptibility. In Vivo. 2010;24:71–4.PubMed

13.

Iversen A, Thune I, McTiernan A, Makar KW, Wilsgaard T, Ellison PT, et al. Genetic polymorphism cyp17 rs2486758 and metabolic risk factors predict daily salivary 17beta-estradiol concentration in healthy premenopausal Norwegian women. The EBBA-I study. J Clin Endocrinol Metab. 2012;97:E852–7.CrossRefPubMed

14.

Chakraborty A, Murthy NS, Chintamani C, Bhatnagar D, Mohil RS, Sharma PC, et al. Cyp17 gene polymorphism and its association with high-risk North Indian breast cancer patients. J Hum Genet. 2007;52:159–65.CrossRefPubMed

15.

Surekha D, Sailaja K, Rao DN, Padma T, Raghunadharao D, Vishnupriya S. Association of a cyp17 gene polymorphism with development of breast cancer in India. Asian Pac J Cancer Prev. 2010;11:1653–7.PubMed

16.

Yazici H, Tigli H, Kadehci Z, Kucucuk S, Saip P, Issever H, et al. Are cyp17 genotypes a biomarker for ovarian cancer in patients with cancer history in their family? Oncol Res. 2006;16:43–7.PubMed

17.

Hou L, Xu J, Gao YT, Rashid A, Zheng SL, Sakoda LC, et al. Cyp17 mspa1 polymorphism and risk of biliary tract cancers and gallstones: a population-based study in Shanghai, China. Int J Cancer. 2006;118:2847–53.CrossRefPubMed

18.

Sangrajrang S, Sato Y, Sakamoto H, Ohnami S, Laird NM, Khuhaprema T, et al. Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women. Int J Cancer. 2009;125:837–43.CrossRefPubMed

19.

Sushko TA, Gilep AA, Usanov SA. Genetics, structure, function, mode of actions and role in cancer development of cyp17. Anticancer Agents Med Chem. 2014;14:66–76.CrossRefPubMed

20.

Yang X, Feng A, Liu F, Li Q, Zhang J, Yang C, et al. Cyp17a1 t-34c polymorphism is not associated with endometrial cancer risk. Tumour Biol. 2013;34:2583–7.CrossRefPubMed

21.

Cote ML, Yoo W, Wenzlaff AS, Prysak GM, Santer SK, Claeys GB, et al. Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women. Carcinogenesis. 2009;30:626–35.PubMedCentralCrossRefPubMed

22.

Rai R, Sharma KL, Tiwari S, Misra S, Kumar A, Mittal B. Dcc (deleted in colorectal carcinoma) gene variants confer increased susceptibility to gallbladder cancer (ref. No.: Gene-d-12-01446). Gene. 2013;518:303–9.CrossRefPubMed

23.

Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.PubMedCentralCrossRefPubMed

24.

Hassanzadeh J, Moradzadeh R, Rajaee Fard A, Tahmasebi S, Golmohammadi P. A comparison of case-control and case-only designs to investigate gene-environment interactions using breast cancer data. Iran J Med Sci. 2012;37:112–8.PubMedCentralPubMed

25.

Jain M, Kumar S, Lal P, Tiwari A, Ghoshal UC, Mittal B. Role of GSTM3 polymorphism in the risk of developing esophageal cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:178–81.CrossRefPubMed

26.

Fan YS, Sasi R, Lee C, Winter JS, Waterman MR, Lin CC. Localization of the human cyp17 gene (cytochrome p450(17 alpha)) to 10q24.3 by fluorescence in situ hybridization and simultaneous chromosome banding. Genomics. 1992;14:1110–1.CrossRefPubMed

27.

Hong CC, Thompson HJ, Jiang C, Hammond GL, Tritchler D, Yaffe M, et al. Association between the t27c polymorphism in the cytochrome p450 c17alpha (cyp17) gene and risk factors for breast cancer. Breast Cancer Res Treat. 2004;88:217–30.CrossRefPubMed

28.

Olson SH, Bandera EV, Orlow I. Variants in estrogen biosynthesis genes, sex steroid hormone levels, and endometrial cancer: a huge review. Am J Epidemiol. 2007;165:235–45.CrossRefPubMed

29.

Lurie G, Maskarinec G, Kaaks R, Stanczyk FZ, Le Marchand L. Association of genetic polymorphisms with serum estrogens measured multiple times during a 2-year period in premenopausal women. Cancer Epidemiol Biomarkers Prev. 2005;14:1521–7.CrossRefPubMed

30.

Chattopadhyay S, Siddiqui S, Akhtar MS, Najm MZ, Deo SV, Shukla NK, et al. Genetic polymorphisms of esr1, esr2, cyp17a1, and cyp19a1 and the risk of breast cancer: a case control study from North India. Tumour Biol. 2014. doi:10.1007/s13277-013-1594-1

31.

Souiden Y, Mahdouani M, Chaieb K, Elkamel R, Mahdouani K. Cyp17 gene polymorphism and prostate cancer susceptibility in a Tunisian population. Cancer Epidemiol. 2011;35:480–4.CrossRefPubMed

32.

Taioli E, Sears V, Watson A, Flores-Obando RE, Jackson MD, Ukoli FA, et al. Polymorphisms in cyp17 and cyp3a4 and prostate cancer in men of African descent. Prostate. 2013;73:668–76.CrossRefPubMed

33.

Nedelcheva Kristensen V, Haraldsen EK, Anderson KB, Lonning PE, Erikstein B, Karesen R, et al. Cyp17 and breast cancer risk: the polymorphism in the 5′ flanking area of the gene does not influence binding to sp-1. Cancer Res. 1999;59:2825–8.PubMed

34.

Mao C, Wang XW, He BF, Qiu LX, Liao RY, Luo RC, et al. Lack of association between cyp17 mspa1 polymorphism and breast cancer risk: a meta-analysis of 22,090 cases and 28,498 controls. Breast Cancer Res Treat. 2010;122:259–65.CrossRefPubMed

35.

Severi G, Hayes VM, Tesoriero AA, Southey MC, Hoang HN, Padilla EJ, et al. The rs743572 common variant in the promoter of cyp17a1 is not associated with prostate cancer risk or circulating hormonal levels. BJU Int. 2008;101:492–6.PubMed

36.

Gaudet MM, Lacey Jr JV, Lissowska J, Peplonska B, Brinton LA, Chanock S, et al. Genetic variation in cyp17 and endometrial cancer risk. Hum Genet. 2008;123:155–62.CrossRefPubMed

37.

Wang F, Zou YF, Feng XL, Su H, Huang F. Cyp17 gene polymorphisms and prostate cancer risk: a meta-analysis based on 38 independent studies. Prostate. 2011;71:1167–77.CrossRefPubMed

38.

Madigan MP, Gao YT, Deng J, Pfeiffer RM, Chang BL, Zheng S, et al. Cyp17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China. Int J Cancer. 2003;107:271–5.CrossRefPubMed

39.

Setiawan VW, Schumacher FR, Haiman CA, Stram DO, Albanes D, Altshuler D, et al. Cyp17 genetic variation and risk of breast and prostate cancer from the national cancer institute breast and prostate cancer cohort consortium (bpc3). Cancer Epidemiol Biomarkers Prev. 2007;16:2237–46.CrossRefPubMed

40.

Abate M, Vanni D, Pantalone A, Salini V. Cigarette smoking and musculoskeletal disorders. Muscles Ligaments Tendons J. 2013;3:63–9.PubMedCentralPubMed

41.

Tansavatdi K, McClain B, Herrington DM. The effects of smoking on estradiol metabolism. Minerva Ginecol. 2004;56:105–14.PubMed

Title: CYP17 polymorphism (rs743572) is associated with increased risk of gallbladder cancer in tobacco users
Authors: Rajani Rai
Kiran L. Sharma
Sanjeev Misra
Ashok Kumar
Balraj Mittal
Publication date: 01-07-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 7/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-1876-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2014

Antitumor activity of a polysaccharide from longan seed on lung cancer cell line A549 in vitro and in vivo

RETRACTED ARTICLE: MMP9 activation triggered by epidermal growth factor induced FoxO1 nuclear exclusion in non-small cell lung cancer

Bladder cancer invasion predictability based on preoperative neutrophil–lymphocyte ratio

Quantitative assessment of the association between L769L and S836S polymorphisms at RET gene and medullary thyroid carcinoma risk

Association of a genetic variant in microRNA-146a with risk of colorectal cancer: a population-based case-control study

LDH5 overexpression is associated with poor survival in patients with solid tumors: a meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer